Nxera Pharma Files Vamorolone Marketing Application in South Korea

Nxera submitted a Marketing Authorization Application to South Korea’s MFDS for vamorolone in DMD, with ODD and GIFT priority review. The company targets approval in 2027 and commercial launch in 2028.